Pancreatic Cancer Research

Clinical trialPhase 2Recruiting

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Phase II Study of Neoadjuvant Folfirinox Chemotherapy Followed by Pembrolizumab Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas

NCT05132504↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Ongoing
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Start
31 August 2022
Expected end
21 May 2027
Enrollment
30 participants
Sites
3
Primary outcomes
Determine if the neoadjuvant FOLFIRINOX chemotherapy followed by pembrolizumab followed by surgery will improve the overall response rate (ORR) for patients with localized, resectable adenocarcinoma of the pancreas.
Sponsor
Other
Results posted
No
Last update
4 August 2026

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 9